Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer and a <i>BRCA</i> mutation: overall survival adjusted for post-progression PARP inhibitor therapy

Matulonis, Ursula

13
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer and a BRCA mutation: overall survival adjusted for post-progression PARP inhibitor therapy

Saturday, March 28, 2015: 2:23 PM

International Ballroom (Hilton Chicago)

U. A. Matulonis¹, P. Harter², C. Gourley³, M. Friedlander⁴, I. B. Vergote⁵, G. J. S. Rustin⁶, A. Fielding⁷, S. Spencer⁷, D. Parry⁷ and J. A. Ledermann⁸
¹Dana-Farber Cancer Institute, Boston, MA, ²Kliniken Essen-Mitte, Essen, Germany, ³University of Edinburgh Cancer Research UK Centre, Edinburgh, United Kingdom, ⁴Prince of Wales Cancer Centre, Randwick, Sydney, Australia, ⁵University Hospital Leuven, Leuven, Belgium, ⁶Mount Vernon Hospital, Middlesex, United Kingdom, ⁷AstraZeneca, Macclesfield, United Kingdom, ⁸University College London, London, United Kingdom

2015 Annual Meeting on Women's Cancer®

March 26 - 31, 2015

Navigation

13
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer and a BRCA mutation: overall survival adjusted for post-progression PARP inhibitor therapy

13 Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer and a BRCA mutation: overall survival adjusted for post-progression PARP inhibitor therapy

13
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer and a BRCA mutation: overall survival adjusted for post-progression PARP inhibitor therapy